A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant with Ribociclib Versus Letrozole with Ribociclib for the First-Line Treatment of ER+, HER2– Advanced Breast Cancer (OPERA-02)
Read more about this trial →← Back to available clinical trials
